Fig. 4From: Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysisCost-effectiveness acceptability curve (CEAC) of the three treatment strategies for China (a) and the USA (b). CEAC represented the uncertainty in cost-effectiveness analysis and provided the reference to the WTP thresholdsBack to article page